Thrombolytic Science International

Thrombolytic Science International is pioneering a sequential dual thrombolytic regimen combining a low dose of tissue plasminogen activator (tPA) with its proprietary compound, mutant prourokinase (HisproUK), to treat acute ischemic stroke and heart attack. The approach aims to be safer and more efficacious than current standards of care by enabling administration on suspicion of a clot, potentially in an ambulance, thereby reducing critical time-to-treatment. The company has advanced its lead program into Phase 2 trials for both stroke and AMI, supported by a strong IP portfolio and a seasoned leadership team with deep expertise in vascular medicine. TSI represents a potentially disruptive player in the cardiovascular and cerebrovascular therapeutic space by addressing a major unmet need in emergency reperfusion therapy.

Bio-inspired sequential dual thrombolytic regimen using a priming dose of tPA followed by a proprietary, clot-targeted mutant prourokinase (HisproUK) that activates only at the site of a degraded clot, enabling safe pre-hospital administration.

TSI competes in the thrombolytic space against the entrenched standard, alteplase (tPA), and the increasingly used tenecteplase. It also faces competition from mechanical thrombectomy for large vessel occlusions in stroke and primary PCI for AMI. Its key differentiator is the potential for pre-hospital, imaging-agnostic administration, a niche not currently addressed by any approved therapy.